Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Int J Radiat Oncol Biol Phys ; 108(4): 979-986, 2020 11 15.
Article in English | MEDLINE | ID: mdl-32599030

ABSTRACT

PURPOSE: Dismal prognosis and limited treatment options for recurrent high-grade glioma have provoked interest in various forms of reirradiation. Pulsed reduced dose rate radiation therapy (pRDR) is a promising technique that exploits low-dose hyper-radiosensitivity of proliferating tumor cells while sparing adjacent nonproliferating normal brain tissue. Large radiation treatment volumes can thus be used to target both contrast-enhancing and FLAIR abnormalities thought to harbor recurrent gross and microscopic disease, respectively. The aim of this retrospective study was to determine whether the addition of pRDR to bevacizumab improves survival over bevacizumab alone for recurrent high-grade glioma. METHODS AND MATERIALS: Eighty patients with recurrent high-grade glioma were included in this study; 47 patients received bevacizumab monotherapy (BEV), and 33 patients received pRDR with bevacizumab (BEV/pRDR). Progression-free survival (PFS) and overall survival were compared between the BEV and BEV/pRDR groups. Regression analysis was performed to identify and control for confounding influences on survival analyses. RESULTS: Significant (P < .05) advantages in PFS (12 vs 4 months; hazard ratio = 2.37) and OS (16 vs. 9 months; hazard ratio = 1.68) were observed with BEV/pRDR compared with BEV alone. CONCLUSIONS: This retrospective analysis suggests that treatment with pRDR in addition to bevacizumab could significantly prolong PFS and overall survival compared with bevacizumab alone for recurrent high-grade glioma.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Bevacizumab/therapeutic use , Brain Neoplasms/therapy , Chemoradiotherapy/methods , Glioma/therapy , Neoplasm Recurrence, Local/therapy , Adult , Aged , Antineoplastic Agents, Immunological/administration & dosage , Bevacizumab/administration & dosage , Brain Neoplasms/mortality , Chemoradiotherapy/mortality , Female , Glioblastoma/mortality , Glioblastoma/therapy , Glioma/mortality , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Progression-Free Survival , Radiotherapy Dosage , Re-Irradiation , Regression Analysis , Retrospective Studies , Young Adult
2.
Oncol Rep ; 38(4): 1932-1940, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28765947

ABSTRACT

Glioblastoma multiforme (GBM) is the most common primary, intracranial malignancy of the central nervous system. The standard treatment protocol, which involves surgical resection, and concurrent radiation with adjuvant temozolomide (TMZ), still imparts a grim prognosis. Ultimately, all GBMs exhibit recurrence or progression, developing resistance to standard treatment. This study demonstrates that GBMs acquire resistance to radiation via upregulation of acid ceramidase (ASAH1) and sphingosine­1-phosphate (Sph-1P). Moreover, inhibition of ASAH1 and Sph-1P, either with humanized monoclonal antibodies, small molecule drugs (i.e. carmofur), or a combination of both, led to suppression of GBM cell growth. These results suggest that ASAH1 and Sph-1P may be excellent targets for the treatment of new GBMs and recurrent GBMs, especially since the latter overexpresses ASAH1.


Subject(s)
Acid Ceramidase/metabolism , Brain Neoplasms/enzymology , Brain Neoplasms/radiotherapy , Glioblastoma/enzymology , Glioblastoma/radiotherapy , Acid Ceramidase/biosynthesis , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Cell Line, Tumor , Glioblastoma/metabolism , Glioblastoma/pathology , Humans , Immunohistochemistry , Lysophospholipids/metabolism , Neoplasm Recurrence, Local/enzymology , Neoplasm Recurrence, Local/pathology , Radiation Tolerance , Sphingosine/analogs & derivatives , Sphingosine/metabolism , Up-Regulation
3.
Oncotarget ; 8(15): 24753-24761, 2017 Apr 11.
Article in English | MEDLINE | ID: mdl-28445970

ABSTRACT

Pediatric brain tumors are the most common solid tumors in children and are also a leading culprit of cancer-related fatalities in children. Pediatric brain tumors remain hard to treat. In this study, we demonstrated that medulloblastoma, pediatric glioblastoma, and atypical teratoid rhabdoid tumors express significant levels of acid ceramidase, where levels are highest in the radioresistant tumors, suggesting that acid ceramidase may confer radioresistance. More importantly, we also showed that acid ceramidase inhibitors are highly effective at targeting these pediatric brain tumors with low IC50 values (4.6-50 µM). This data suggests acid ceramidase as a novel drug target for adjuvant pediatric brain tumor therapies. Of these acid ceramidase inhibitors, carmofur has seen clinical use in Japan since 1981 for colorectal cancers and is a promising drug to undergo further animal studies and subsequently a clinical trial as a treatment for pediatric patients with brain tumors.


Subject(s)
Acid Ceramidase/therapeutic use , Brain Neoplasms/drug therapy , Acid Ceramidase/pharmacology , Animals , Brain Neoplasms/pathology , Child , Humans , Mice
5.
Oncotarget ; 8(68): 112662-112674, 2017 Dec 22.
Article in English | MEDLINE | ID: mdl-29348854

ABSTRACT

Glioblastoma remains the most common, malignant primary cancer of the central nervous system with a low life expectancy and an overall survival of less than 1.5 years. The treatment options are limited and there is no cure. Moreover, almost all patients develop recurrent tumors, which typically are more aggressive. Therapeutically resistant glioblastoma or glioblastoma stem-like cells (GSCs) are hypothesized to cause this inevitable recurrence. Identifying prognostic biomarkers of glioblastoma will potentially advance knowledge about glioblastoma tumorigenesis and enable discovery of more effective therapies. Proteomic analysis of more than 600 glioblastoma-specific proteins revealed, for the first time, that expression of acid ceramidase (ASAH1) is associated with poor glioblastoma survival. CD133+ GSCs express significantly higher ASAH1 compared to CD133- GSCs and serum-cultured glioblastoma cell lines, such as U87MG. These findings implicate ASAH1 as a plausible independent prognostic marker, providing a target for a therapy tailored toward GSCs. We further demonstrate that ASAH1 inhibition increases cellular ceramide level and induces apoptosis. Strikingly, U87MG cells, and three different patient-derived glioblastoma stem-like cancer cell lines were efficiently killed, through apoptosis, by three different known ASAH1 inhibitors with IC50's ranging from 11-104 µM. In comparison, the standard glioblastoma chemotherapy agent, temozolomide, had minimal GSC-targeted effects at comparable or even higher concentrations (IC50 > 750 µM against GSCs). ASAH1 is identified as a de novo glioblastoma drug target, and ASAH1 inhibitors, such as carmofur, are shown to be highly effective and to specifically target glioblastoma GSCs. Carmofur is an ASAH1 inhibitor that crosses the blood-brain barrier, a major bottleneck in glioblastoma treatment. It has been approved in Japan since 1981 for colorectal cancer therapy. Therefore, it is poised for repurposing and translation to glioblastoma clinical trials.

6.
J Magn Reson Imaging ; 45(1): 51-58, 2017 01.
Article in English | MEDLINE | ID: mdl-27227824

ABSTRACT

PURPOSE: To evaluate magnetic resonance imaging (MRI) artifacts near metallic spinal instrumentation using both conventional metal artifact reduction sequences (MARS) and 3D multispectral imaging sequences (3D-MSI). MATERIALS AND METHODS: Both MARS and 3D-MSI images were acquired in 10 subjects with titanium spinal hardware on a 1.5T GE 450W scanner. Clinical computed tomography (CT) images were used to measure the volume of the implant using seed-based region growing. Using 30-40 landmarks, the MARS and 3D-MSI images were coregistered to the CT images. Three independent users manually segmented the artifact volume from both MR sequences. For five L-spine subjects, one user independently segmented the nerve root in both MARS and 3D-MSI images. RESULTS: For all 10 subjects, the measured artifact volume for the 3D-MSI images closely matched that of the CT implant volume (absolute error: 4.3 ± 2.0 cm3 ). The MARS artifact volume was ∼8-fold higher than that of the 3D-MSI images (30.7 ± 20.2, P = 0.002). The average nerve root volume for the MARS images was 24 ± 7.3% lower than the 3D-MSI images (P = 0.06). CONCLUSION: Compared to 3D-MSI images, the higher-resolution MARS images may help study features farther away from the implant surface. However, the MARS images retained substantial artifacts in the slice-dimension that result in a larger artifact volume. These artifacts have the potential to obscure physiologically relevant features, and can be mitigated with 3D-MSI sequences. Hence, MR study protocols may benefit with the inclusion both MARS and 3D-MSI sequences to accurately study pathology near the spine. LEVEL OF EVIDENCE: 2 J. Magn. Reson. Imaging 2017;45:51-58.


Subject(s)
Cervical Vertebrae/diagnostic imaging , Imaging, Three-Dimensional/methods , Internal Fixators , Lumbar Vertebrae/diagnostic imaging , Magnetic Resonance Imaging/methods , Metals , Spinal Fusion/instrumentation , Aged , Cervical Vertebrae/surgery , Female , Humans , Image Enhancement/methods , Image Interpretation, Computer-Assisted/methods , Lumbar Vertebrae/surgery , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
7.
Tomography ; 2(3): 223-228, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27774518

ABSTRACT

Magnetic resonance imaging (MRI) is used to diagnose and monitor brain tumors. Extracting additional information from medical imaging and relating it to a clinical variable of interest is broadly defined as radiomics. Here, multiparametric MRI radiomic profiles (RPs) of de novo glioblastoma (GBM) brain tumors is related with patient prognosis. Clinical imaging from 81 patients with GBM before surgery was analyzed. Four MRI contrasts were aligned, masked by margins defined by gadolinium contrast enhancement and T2/fluid attenuated inversion recovery hyperintensity, and contoured based on image intensity. These segmentations were combined for visualization and quantification by assigning a 4-digit numerical code to each voxel to indicate the segmented RP. Each RP volume was then compared with overall survival. A combined classifier was then generated on the basis of significant RPs and optimized volume thresholds. Five RPs were predictive of overall survival before therapy. Combining the RP classifiers into a single prognostic score predicted patient survival better than each alone (P < .005). Voxels coded with 1 RP associated with poor prognosis were pathologically confirmed to contain hypercellular tumor. This study applies radiomic profiling to de novo patients with GBM to determine imaging signatures associated with poor prognosis at tumor diagnosis. This tool may be useful for planning surgical resection or radiation treatment margins.

8.
Ann Diagn Pathol ; 24: 30-4, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27649951

ABSTRACT

Spinal meningiomas associated with bone formation and hematopoiesis are rare tumors with only 3 prior case reports in the literature. We describe a case report of a woman who presented with back pain and an isolated event of urinary incontinence. A calcified spinal canal mass at T8 was identified on computed tomographic and magnetic resonance imaging. A gross total resection of the tumor was performed and pathologic examination showed a meningioma, World Health Organization grade 1, containing bone and bone marrow elements. A review of previously reported cases and a discussion of possible mechanisms of bone and hematopoiesis development in meningioma are presented.


Subject(s)
Hematopoiesis/physiology , Meningeal Neoplasms/pathology , Meningioma/diagnosis , Meningioma/pathology , Osteoblasts/pathology , Female , Humans , Magnetic Resonance Imaging/methods , Meningeal Neoplasms/diagnosis , Middle Aged , Spinal Cord/pathology , Tomography, X-Ray Computed/methods
9.
Eur Spine J ; 24(11): 2458-67, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26238936

ABSTRACT

PURPOSE: Dynamic contrast-enhanced MRI (DCE-MRI) was used to investigate the associations between intervertebral disc degeneration and changes in perfusion and diffusion in the disc endplates. METHODS: 56 participants underwent MRI scans. Changes in DCE-MRI signal enhancement in the endplate regions were analyzed. Also, a group template was generated for the endplates and enhancement maps were registered to this template for group analysis. RESULTS: DCE-MRI enhancement changed significantly in cranial endplates with increased degeneration. A similar trend was observed for caudal endplates, but it was not significant. Group-averaged enhancement maps revealed major changes in spatial distribution of endplate perfusion and diffusion with increasing disc degeneration especially in peripheral endplate regions. CONCLUSIONS: Increased enhancement in the endplate regions of degenerating discs might be an indication of ongoing damage in these tissues. Therefore, DCE-MRI could aid in understanding the pathophysiology of disc degeneration. Moreover, it could be used in the planning of novel treatments such as stem cell therapy.


Subject(s)
Intervertebral Disc Degeneration/diagnosis , Intervertebral Disc/blood supply , Adult , Case-Control Studies , Contrast Media/metabolism , Diffusion , Female , Humans , Intervertebral Disc/metabolism , Intervertebral Disc Degeneration/metabolism , Intervertebral Disc Degeneration/physiopathology , Lumbar Vertebrae/blood supply , Magnetic Resonance Imaging/methods , Male , Middle Aged , Young Adult
10.
Neuro Oncol ; 16(12): 1599-606, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25059209

ABSTRACT

BACKGROUND: Recent conflicting reports have found both brain tumor hypercellularity and necrosis in regions of restricted diffusion on MRI-derived apparent diffusion coefficient (ADC) images. This study precisely compares ADC and cell density voxel by voxel using postmortem human whole brain samples. METHODS: Patients with meningioma were evaluated to determine a normative ADC distribution within benign fluid attenuated inversion recovery (FLAIR) T2/hyperintensity surrounding tumor. This distribution was used to calculate a minimum ADC threshold to define regions of ADC-FLAIR mismatch (AFMM), where restricted diffusion presented in conjunction with T2/FLAIR hyperintensity. Contrast-enhancing voxels were excluded from this analysis. AFMM maps were generated using imaging acquired prior to death in 7 patients with high-grade glioma who eventually donated their brains upon death. Histological samples were taken from numerous regions of abnormal FLAIR and AFMM. Each sample was computationally processed to determine cell density. Custom software was then used to downsample coregistered microscopic histology to the more coarse MRI resolution. A voxel-by-voxel evaluation comparing ADC and cellularity was then performed. RESULTS: An ADC threshold of 0.929 × 10(-3) mm(2)/s was calculated from meningioma-induced edema and was used to define AFMM. Regions of AFMM showed significantly greater cell density in 6 of 7 high-grade glioma cases compared with regions of hyperintense FLAIR alone (P < .0001). Two patients had small regions of diffusion-restricted necrosis that had significantly lower ADC than nearby hypercellularity. CONCLUSIONS: Regions of AFMM contain hypercellularity except for regions with extremely restricted diffusion, where necrosis is present.


Subject(s)
Diffusion Magnetic Resonance Imaging/methods , Glioma/pathology , Meningeal Neoplasms/pathology , Meningioma/pathology , Adult , Aged , Aged, 80 and over , Brain Edema/pathology , Diffusion , Female , Humans , Male , Middle Aged , Necrosis
11.
Physiol Genomics ; 46(13): 467-81, 2014 Jul 01.
Article in English | MEDLINE | ID: mdl-24803679

ABSTRACT

Cancer is a complex disease; glioblastoma (GBM) is no exception. Short survival, poor prognosis, and very limited treatment options make it imperative to unravel the disease pathophysiology. The critically important identification of proteins that mediate various cellular events during disease is made possible with advancements in mass spectrometry (MS)-based proteomics. The objective of our study is to identify and characterize proteins that are differentially expressed in GBM to better understand their interactions and functions that lead to the disease condition. Further identification of upstream regulators will provide new potential therapeutic targets. We analyzed GBM tumors by SDS-PAGE fractionation with internal DNA markers followed by liquid chromatography-tandem mass spectrometry (MS). Brain tissue specimens obtained for clinical purposes during epilepsy surgeries were used as controls, and the quantification of MS data was performed by label-free spectral counting. The differentially expressed proteins were further characterized by Ingenuity Pathway Analysis (IPA) to identify protein interactions, functions, and upstream regulators. Our study identified several important proteins that are involved in GBM progression. The IPA revealed glioma activation with z score 2.236 during unbiased core analysis. Upstream regulators STAT3 and SP1 were activated and CTNNα was inhibited. We verified overexpression of several proteins by immunoblot to complement the MS data. This work represents an important step towards the identification of GBM biomarkers, which could open avenues to identify therapeutic targets for better treatment of GBM patients. The workflow developed represents a powerful and efficient method to identify biomarkers in GBM.


Subject(s)
Biomarkers, Tumor/analysis , Biomarkers, Tumor/metabolism , Brain Neoplasms/metabolism , Glioblastoma/metabolism , Mass Spectrometry/methods , Proteomics/methods , Adult , Aged , Brain Neoplasms/chemistry , Female , Glioblastoma/chemistry , Humans , Male , Middle Aged , Staining and Labeling , Young Adult
12.
Neuro Oncol ; 16(6): 880-8, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24431219

ABSTRACT

BACKGROUND: The anti-VEGF antibody, bevacizumab, is standard treatment for patients with recurrent glioblastoma. In this setting, traditional anatomic MRI methods such as post-contrast T1-weighted and T2-weighted imaging are proving unreliable for monitoring response. Here we evaluate the prognostic significance of pre- and posttreatment relative cerebral blood volume (rCBV) derived from dynamic susceptibility contrast MRI to predict response to bevacizumab. METHODS: Thirty-six participants with recurrent high-grade gliomas who underwent rCBV imaging 60 days before and 20-60 days after starting bevacizumab treatment were enrolled. Tumor regions of interest (ROIs) were determined from deltaT1 maps computed from the difference between standardized post and precontrast T1-weighted images. Both pre- and posttreatment rCBV maps were corrected for leakage and standardized (stdRCBV) to a consistent intensity scale. The Kaplan-Meier method was used to determine if either the pre- or post-bevacizumab stdRCBV within the tumor ROI was predictive of overall survival (OS) or progression free survival (PFS). RESULTS: The OS was significantly longer if either the pre- (380d vs 175d; P=.0024) or posttreatment stdRCBV (340d vs 186d; P = .0065) was <4400. The posttreatment stdRCBV was also predictive of PFS (167d vs 78d; P = .0006). When the stdRCBV values were both above versus both below threshold, the OS was significantly worse (100.5d vs 395d; P < .0001). With a 32.5% decrease in stdRCBV, the risk of death was reduced by about 68% but increased by 140% with a 29% increase in stdRCBV. CONCLUSIONS: Standardized rCBV is predictive of OS and PFS in patients with recurrent high-grade brain tumor treated with bevacizumab.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Brain Neoplasms/drug therapy , Cerebral Cortex/blood supply , Glioblastoma/drug therapy , Magnetic Resonance Imaging/methods , Adult , Aged , Bevacizumab , Brain Neoplasms/blood supply , Contrast Media , Female , Glioblastoma/blood supply , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Prognosis , Survival Analysis
13.
J Neurooncol ; 114(3): 291-7, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23813291

ABSTRACT

White matter injury is a known complication of whole brain radiation (WBRT). Little is known about the factors that predispose a patient to such injury. The current study used MR volumetrics to examine risk factors, in particular the influence of pre-treatment white matter health, in developing white matter change (WMC) following WBRT. Thirty-four patients with unilateral metastatic disease underwent FLAIR MRI pre-treatment and at several time points following treatment. The volume of abnormal FLAIR signal in the white matter was measured in the hemisphere contralateral to the diseased hemisphere at each time point. Analyses were restricted to the uninvolved hemisphere to allow for the measurement of WBRT effects without the potential confounding effects of the disease on imaging findings. The relationship between select pre-treatment clinical variables and the degree of WMC following treatment was examined using correlational and regression based analyses. Age when treated and volume of abnormal FLAIR prior to treatment were significantly associated with WMC following WBRT; however, pre-treatment FLAIR volume was the strongest predictor of post-treatment WMCs. Age did not add any predictive value once white matter status was considered. No significant relationships were found between biological equivalent dose and select cerebrovascular risk factors (total glucose, blood pressure, BMI) and development of WMCs. The findings from this study identify pre-treatment white matter health as an important risk factor in developing WMC following WBRT. This information can be used to make more informed decisions and counsel patients on their risk for treatment effects.


Subject(s)
Brain Neoplasms/radiotherapy , Cranial Irradiation , Leukoencephalopathies/diagnostic imaging , Magnetic Resonance Imaging , Adult , Aged , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Female , Follow-Up Studies , Humans , Leukoencephalopathies/pathology , Male , Middle Aged , Prognosis , Radiation Tolerance , Radiography , Retrospective Studies , Risk Factors
14.
J Magn Reson Imaging ; 38(4): 868-75, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23389889

ABSTRACT

PURPOSE: To characterize the influence of perfusion on the measurement of diffusion changes over time when ADC is computed using standard two-point methods. MATERIALS AND METHODS: Functional diffusion maps (FDMs), which depict changes in diffusion over time, were compared with rCBV changes in patients with brain tumors. The FDMs were created by coregistering and subtracting ADC maps from two time points and categorizing voxels where ADC significantly increased (iADC), decreased (dADC), or did not change (ncADC). Traditional FDMs (tFDMs) were computed using b = 0,1000 s/mm(2). Flow-compensated FDMs (fcFDMs) were calculated using b = 500,1000 s/mm(2). Perfusion's influence on FDMs was determined by evaluating changes in rCBV in areas where the ADC change significantly differed between the two FDMs. RESULTS: The mean ΔrCBV in voxels that changed from iADC (dADC) on the tFDM to ncADC on the fcFDM was significantly greater (less) than zero. In addition, mean ΔrCBV in iADC (dADC) voxels on the tFDM was significantly higher (lower) than in iADC (dADC) voxels on the fcFDM. CONCLUSION: The ability to accurately identify changes in diffusion on traditional FDMs is confounded in areas where perfusion and diffusion changes are colocalized. Flow-compensated FDMs, which use only non-zero b-values, should therefore be the standard approach.


Subject(s)
Brain Neoplasms/pathology , Diffusion Magnetic Resonance Imaging , Glioblastoma/pathology , Perfusion , Algorithms , Astrocytoma/pathology , Female , Glioma/pathology , Humans , Image Processing, Computer-Assisted , Male , Meningioma/pathology , Oligodendroglioma/pathology , Reproducibility of Results , Retrospective Studies
15.
Neuro Oncol ; 15(4): 442-50, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23382287

ABSTRACT

BACKGROUND: Standard pre- and postcontrast (T1 + C) anatomical MR imaging is proving to be insufficient for accurately monitoring bevacizumab treatment response in recurrent glioblastoma (GBM). We present a novel imaging biomarker that detects abnormal tumor vasculature exhibiting both arterial and venous perfusion characteristics. We hypothesized that a decrease in the extent of this abnormal vasculature after bevacizumab treatment would predict treatment efficacy and overall survival. METHODS: Dynamic susceptibility contrast perfusion MRI was gathered in 43 patients with high-grade glioma. Independent component analysis separated vasculature into arterial and venous components. Voxels with perfusion characteristics of both arteries and veins (ie, arterio-venous overlap [AVOL]) were measured in patients with de novo untreated GBM and patients with recurrent high-grade glioma before and after bevacizumab treatment. Treated patients were separated on the basis of an increase or decrease in AVOL volume (+/-ΔAVOL), and overall survival following bevacizumab onset was then compared between +/-ΔAVOL groups. RESULTS: AVOL in untreated GBM was significantly higher than in normal vasculature (P < .001). Kaplan-Meier survival curves revealed a greater median survival (348 days) in patients with GBM with a negative ΔAVOL after bevacizumab treatment than in patients with a positive change (197 days; hazard ratio, 2.51; P < .05). Analysis of patients with combined grade III and IV glioma showed similar results, with median survivals of 399 days and 153 days, respectively (hazard ratio, 2.71; P < .01). Changes in T1+C volume and ΔrCBV after treatment were not significantly different across +/-ΔAVOL groups, and ΔAVOL was not significantly correlated with ΔT1+C or ΔrCBV. CONCLUSIONS: The independent component analysis dynamic susceptibility contrast-derived biomarker AVOL adds additional information for determining bevacizumab treatment efficacy.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Brain Neoplasms/drug therapy , Contrast Media , Glioblastoma/drug therapy , Magnetic Resonance Imaging , Neovascularization, Pathologic/diagnosis , Wavelet Analysis , Angiogenesis Inhibitors/therapeutic use , Bevacizumab , Brain Neoplasms/blood supply , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Follow-Up Studies , Glioblastoma/blood supply , Glioblastoma/mortality , Glioblastoma/pathology , Humans , Neoplasm Grading , Neovascularization, Pathologic/mortality , Neovascularization, Pathologic/prevention & control , Prognosis , Retrospective Studies , Survival Rate
16.
Magn Reson Med ; 65(4): 1131-43, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21413079

ABSTRACT

The purpose of this study was to develop a voxel-wise analytical solution to a glioma growth model using serial diffusion MRI. These cell invasion, motility, and proliferation level estimates (CIMPLE maps) provide quantitative estimates of microscopic tumor growth dynamics. After an analytical solution was found, noise simulations were performed to predict the effects that perturbations in apparent diffusion coefficient values and the time between apparent diffusion coefficient map acquisitions would have on the accuracy of CIMPLE maps. CIMPLE maps were then created for 53 patients with gliomas with WHO grades of II-IV. MR spectroscopy estimates of the choline-to-N-acetylaspartate ratio were compared to cell proliferation estimates in CIMPLE maps using Pearson's correlation analysis. Median differences in cell proliferation and diffusion rates between WHO grades were compared. A strong correlation (R(2) = 0.9714) and good spatial correspondence were observed between MR spectroscopy measurements of the choline-to-N-acetylaspartate ratio and CIMPLE map cell proliferation rate estimates. Estimates of cell proliferation and diffusion rates appear to be significantly different between low- (WHO II) and high-grade (WHO III-IV) gliomas. Cell diffusion rate (motility) estimates are highly dependent on the time interval between apparent diffusion coefficient map acquisitions, whereas cell proliferation rate estimates are additionally influenced by the level of noise present in apparent diffusion coefficient maps.


Subject(s)
Brain Neoplasms/pathology , Brain Neoplasms/physiopathology , Diffusion Magnetic Resonance Imaging/methods , Glioblastoma/pathology , Glioblastoma/physiopathology , Image Interpretation, Computer-Assisted/methods , Models, Biological , Algorithms , Cell Proliferation , Computer Simulation , Humans , Image Enhancement/methods , Imaging, Three-Dimensional/methods , Neoplasm Invasiveness , Reproducibility of Results , Sensitivity and Specificity
17.
Epilepsy Res ; 94(1-2): 102-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21334178

ABSTRACT

PURPOSE: Subdural electrodes are implanted for recording intracranial EEG (iEEG) in cases of medically refractory epilepsy as a means to locate cortical regions of seizure onset amenable to surgical resection. Without the aid of imaging-derived 3D electrode models for surgical planning, surgeons have relied on electrodes remaining stationary from the time between placement and follow-up resection. This study quantifies electrode shift with respect to the cortical surface occurring between electrode placement and subsequent reopening. METHODS: CT and structural MRI data were gathered following electrode placement on 10 patients undergoing surgical epilepsy treatment. MRI data were used to create patient specific post-grid 3D reconstructions of cortex, while CT data were co-registered to the MRI and thresholded to reveal electrodes only. At the time of resective surgery, the craniotomy was reopened and electrode positions were determined using intraoperative navigational equipment. Changes in position were then calculated between CT coordinates and intraoperative electrode coordinates. RESULTS: Five out of ten patients showed statistically significant overall magnitude differences in electrode positions (mean: 7.2mm), while 4 exhibited significant decompression based shift (mean: 4.7mm), and 3 showed significant shear displacement along the surface of the brain (mean: 7.1mm). DISCUSSION: Shift in electrode position with respect to the cortical surface has never been precisely measured. We show that in 50% of our cases statistically significant shift occurred. These observations demonstrate the potential utility of complimenting electrode position measures at the reopening of the craniotomy with 3D electrode and brain surface models derived from post-implantation CT and MR imaging for better definition of surgical boundaries.


Subject(s)
Electrodes, Implanted , Epilepsy/pathology , Imaging, Three-Dimensional , Subdural Space/pathology , Subdural Space/surgery , Adult , Analysis of Variance , Brain Mapping , Craniotomy/methods , Electrodes, Implanted/adverse effects , Electroencephalography/methods , Epilepsy/diagnostic imaging , Epilepsy/surgery , Female , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Reproducibility of Results , Tomography, X-Ray Computed/methods , Young Adult
18.
Neurosurgery ; 68(1 Suppl Operative): 152-60; discussion 160-1, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21206319

ABSTRACT

BACKGROUND: Accurate localization and visualization of subdural electrodes implanted for intracranial electroencephalography in cases of medically refractory epilepsy remains a challenging clinical problem. OBJECTIVE: We introduce a technique for creating accurate 3-dimensional (3D) brain models with electrode overlays, ideal for resective surgical planning. METHODS: Our procedure uses postimplantation magnetic resonance imaging (MRI) and computed tomographic (CT) imaging to create 3D models of compression-affected brain combined with intensity-thresholded CT-derived electrode models using freely available software. Footprints, or "shadows," beneath electrodes are also described for better visualization of sulcus-straddling electrodes. Electrode models were compared with intraoperative photography for validation. RESULTS: Realistic representations of intracranial electrode positions on patient-specific postimplantation MRI brain renderings were reliably created and proved accurate when compared with photographs. Electrodes placed interhemispherically were also visible with our rendering technique. Electrode shadows were useful in locating electrodes that straddle sulci. CONCLUSION: We present an accurate method for visualizing subdural electrodes on brain compression effected 3D models that serves as an ideal platform for surgical planning.


Subject(s)
Electrodes, Implanted , Imaging, Three-Dimensional/methods , Magnetic Resonance Imaging/methods , Preoperative Care/methods , Subdural Space/surgery , Tomography, X-Ray Computed/methods , Epilepsy/surgery , Female , Humans , Male , Middle Aged , Software
19.
J Neurooncol ; 102(1): 95-103, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20798977

ABSTRACT

Anti-angiogenic agents targeting brain tumor neovasculature may increase progression-free survival in patients with recurrent malignant gliomas. However, when these patients do recur it is not always apparent as an increase in enhancing tumor volume on MRI, which has been the standard of practice for following patients with brain tumors. Therefore alternative methods are needed to evaluate patients treated with these novel therapies. Furthermore, a method that can also provide useful information for the evaluation of conventional therapies would provide an important advantage for general applicability. Diffusion-weighted magnetic resonance imaging (DWI) has the potential to serve as a valuable biomarker for these purposes. In the current study, we explore the prognostic ability of functional diffusion maps (fDMs), which examine voxel-wise changes in the apparent diffusion coefficient (ADC) over time, applied to regions of fluid-attenuated inversion recovery (FLAIR) abnormalities in patients with malignant glioma, treated with either anti-angiogenic or cytotoxic therapies. Results indicate that the rate of change in fDMs is an early predictor of tumor progression, time to progression and overall survival for both treatments, suggesting the application of fDMs in FLAIR abnormal regions may be a significant advance in brain tumor biomarker technology.


Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/therapy , Diffusion Magnetic Resonance Imaging , Glioma/diagnosis , Glioma/therapy , Neovascularization, Pathologic/diagnosis , Neovascularization, Pathologic/therapy , Brain Neoplasms/blood supply , Disease Progression , Glioma/blood supply , Humans , Neoplasm Staging , Prognosis , Survival Rate , Tumor Burden
20.
J Magn Reson Imaging ; 31(3): 538-48, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20187195

ABSTRACT

PURPOSE: To present comprehensive examinations of the assumptions made in functional diffusion map (fDM) analyses and provide a biological basis for fDM classification. MATERIALS AND METHODS: Sixty-nine patients with gliomas were enrolled in this study. To determine the sensitivity of apparent diffusion coefficients (ADCs) to cellularity, cell density from stereotactic biopsy specimens was correlated with preoperative ADC maps. For definition of ADC thresholds used for fDMs, the 95% confidence intervals (CI) for changes in voxel-wise ADC measurements in normal appearing tissue was analyzed. The sensitivity and specificity to progressing disease was examined using both radiographic and neurological criteria. RESULTS: Results support the hypothesis that ADC is inversely proportional to cell density with a sensitivity of 1.01 x 10(-7) [mm(2)/s]/[nuclei/mm(2)]. The 95% CI for white matter = 0.25 x 10(-3) mm(2)/s, gray matter = 0.31 x 10(-3) mm(2)/s, a mixture of white and gray matter = 0.40 x 10(-3) mm(2)/s, and a mixture of white matter, gray matter, and cerebrospinal fluid = 0.75 x 10(-3) mm(2)/s. Application of these measurements as ADC thresholds produce varying levels of sensitivity and specificity to disease progression, which were all significantly better than chance. CONCLUSION: This study suggests fDMs are valid biomarkers for brain tumor cellularity.


Subject(s)
Brain Neoplasms/pathology , Brain Neoplasms/physiopathology , Diffusion Magnetic Resonance Imaging/methods , Glioma/pathology , Glioma/physiopathology , Image Interpretation, Computer-Assisted/methods , Models, Biological , Adult , Aged , Aged, 80 and over , Algorithms , Computer Simulation , Female , Humans , Image Enhancement/methods , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...